15th CROI
4th IAS Conference
XVI International AIDS Conference
13th CROI
3rd IAS Conference
12th CROI
XV International AIDS Conference
11th CROI
2nd IAS Conference on HIV and Pathogenesis
XII International HIV Drug Resistance Workshop
XIV International AIDS Conference
41st ICAAC

---

Emtricitabine Main Page

Main New/Newsworthy

Home Page

---

Last Update:  February 07, 2008
Documents identified with this icon  are in Portable Document Format (PDF) and require the Adobe Acrobat Reader.
Perinatal Data are integrated with Perinatal Conference Data in the Perinatal Data Page.
Pediatric  Data are integrated with Pediatric  Conference Data in the Pediatric Data Page

	Lack of clinically relevant drug-drug interaction between ritonavir-boosted GS-9137 (GS-9137/r) and emtricitabine (FTC)/ tenofovir disoproxil fumarate (TDF) Ramanathan S., Skillington J., Plummer A., et al Abstract
	The immunologic and virologic success of lamivudine and emtricitabine in treatment-experienced patients with the M184V mutation: Are three active agents really necessary? Furtek K., Crum-Cianflone N., Bavaro M., et al Abstract

---

13th Conference on Retroviruses and Opportunistic Infections

---

POSTER Steady-state Pharmacokinetic Evaluation of Emtricitabine in Neonates Exposed to HIV in utero MR Blum, D Ndiweni, G Chittick, et al  13 CROI PDF Poster     Abstract   TREC Response in P1021: A Once-daily Regimen of Emtricitabine, Didanosine, and Efavirenz in Previously Naive Children R Dickover, D Smith, P Britto, et al Abstract   In a Paired-sample Comparison, the Presence of Thymidine Analogue Mutations, but not Other Common Nucleoside Reverse Transcriptase Inhibitor Mutations Has a Differential Effect on Emtricitabine and Lamivudine Susceptibility L Ross, N Parkin, M Underwood, et al  Abstract   Phase I/II Study of a Once-daily Regimen of Emtricitabine, Didanosine, and Efavirenz in HIV-infected, Therapy-naïve Children and Adolescents: PACTG Protocol 1021 R McKinney, M Rathore, C Hu, et al Abstract

---

3rd IAS Conference on HIV and Pathogenesis

---

Evaluation of Hyperpigmentation in HIV-Infected Patients Receiving Emtricitabine Rashbaum B. Abstract   In Vitro Evaluation of the Anti-HIV Activity and Metabolic Interactions of Tenofovir and Emtricitabine Myrick F., Vela JE., Ray AS., Abstract   Lack of resistance to tenofovir at week 48 and impact of baseline resistance mutations on treatment response in study 934 McColl D., Margot N., Lu B., et al Abstract

---

12th Conference on Retroviruses and Opportunistic Infections

---

	PDF POSTER Comparison of the Phenotypic Effects of NRTI Mutations on Emtricitabine and Lamivudine L Ross , N Parkin, M Underwood PDF Poster     Abstract
	Hematologic Benefit of Switching from Regimens Combining Protease Inhibitors and Zidovudine plus Lamivudine to Once-daily Emtricitabine, Didanosine, and Efavirenz. A Sub-study of the ANRS 099 ALIZE Trial JM Molina, M Bentata, M Garré, et al   Abstract